Grazax + Aerius

Phase 3

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Allergic Rhinoconjunctivitis

Drug Information

Target Indication

Allergic Rhinoconjunctivitis

Clinical Trial

Last updated: 6/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Regulatory Approvals

EMA1/15/2001

Aerius

Aerius is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria.

Drug Science

Mechanism of action & safety profile

Developer

ALK-B.CO

ALK-Abelló A/S

Related Pipeline

Allergic Rhinitis Due to Dermatophagoides Farinae

Allergic Rhinoconjunctivitis

Allergy

Asthma

Rhinitis Allergic

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts